Objective To investigate the pleiotropic effects of a calcium antagonist (amlodipine) on early atherosclerosis development in the presence and absence of an HMG-CoA-reductase inhibitor (atorvastatin) in apolipoprotein E*3-Leiden/human C-reactive protein (E3L/CRP) transgenic mice.
Introduction
Atherosclerosis is a multifactorial disease, and the underlying cause of myocardial infarction and stroke. Factors contributing to the atherosclerotic process are hypertension, elevated low-density lipoprotein (LDL)-cholesterol levels, low high-density lipoprotein (HDL)-cholesterol levels, obesity, smoking, diabetes and genetic factors 1 . Drugs have been developed that effectively reduce these risk factors, such as calcium antagonists (CAs) which lower blood pressure, and HMG-CoA-reductase inhibitors (statins) which inhibit cholesterol synthesis and thereby lower plasma cholesterol levels.
The primary action of CAs is to reduce blood pressure by inhibiting Ca 2+ influx through voltage-gated transmembrane channels. However, CAs may influence a number of other key processes in atherosclerosis such as the oxidation of LDL and smooth muscle cell (SMC) migration and proliferation 2, 3 . Several studies have demonstrated that the antiatherosclerotic effect of CAs was limited to the first stages of atherosclerosis 4, 5 . Pre-existing lesions were not influenced by CA therapy as far as angiographic progression or regression was concerned. More recent data have demonstrated that the CA amlodipine had no effect on the progression of atherosclerosis or cardiovascular events, but was associated with a reduction in cardiovascular morbidity 6 . These data failed to support the hypothesis that amlodipine alters the development or progression of minimal coronary artery lesions 6 .
However, the recently published CAMELOT study has demonstrated that administration of amlodipine to patients with coronary artery disease (CAD) and normal blood pressure resulted in reduced cardiovascular events, and assessment of atherosclerosis progression with intravascular ultrasound showed that treatment with amlodipine slowed progression of atherosclerosis 7 . Therefore, the anti-atherosclerotic effects of CAs remain under debate.
Statins improve the survival rate of patients with hypercholesterolemia and CAD primarily by lowering circulating LDL cholesterol levels. Moreover, statins have a number of important pharmacological effects in addition to reducing the plasma LDL cholesterol level 8, 9 .
Combining CA and statin therapy may be more successful than either therapy alone as indicated by retrospective analysis of the data from the REGRESS study, where treatment of patients with both pravastatin and a CA was found to be more successful in retarding the progression of atherosclerosis than treatment with pravastatin alone 10 . Therapy with CAs alone had no effect on the progression of atherosclerosis in that study. This suggests that
CAs only exert an anti-atherosclerotic effect in the presence of a cholesterol-lowering agent such as an HMG-CoA-reductase inhibitor.
The cardiovascular risk factor C-reactive protein (CRP) is a major acute phase reactant in man but not in mice. In humans, plasma CRP levels can be reduced by statin therapy [11] [12] [13] [14] . In the present study we tested whether treatment with the CA amlodipine had antiatherosclerotic effects, independent of blood pressure lowering, in E3L/CRP transgenic mice.
Additionally, we investigated whether a potential anti-atherosclerotic effect of a CA is only seen after lipid lowering. To this end, mice were treated with amlodipine, atorvastatin or the combination of both, followed by quantification of atherosclerotic lesion area in the aortic root. Furthermore, to test whether atorvastatin has any anti-atherosclerotic effects beyond the lipid-lowering effect, a fifth group was added, the low-cholesterol group, having similar plasma cholesterol levels as the atorvastatin-treated mice.
Methods

Mice
ApoE*3-Leiden (E3L) transgenic mice are an established model for the study of hyperlipidemia and atherosclerosis 16 and have been shown to be responsive to lipidlowering therapy [17] [18] [19] . Male E3L +/-/CRP +/-mice were obtained by cross-breeding female E3L transgenic mice with heterozygous male CRP transgenic mice, originally described by
Ciliberto et al. 20, 21 . Identification of mice transgenic for E3L was performed by an ELISA for human ApoE 16 . The presence of the human CRP gene was assessed by PCR. Male E3L/CRP transgenic mice (mean age: 14 weeks at entry into the study) were used, because female CRP-transgenic mice do not constitutively express CRP 22 .
Experimental design
Before the start of the study, all animals were kept on a standard mouse chow (Hope Farms, The Netherlands). During a three-week run-in period, all animals received a semisynthetic high-cholesterol diet 23 Serum amyloid A (SAA) was determined by ELISA, as prescribed by the manufacturer (Biosource International, Nivelles, Belgium).
Endothelial activation was assessed by determination of the plasma levels of von
Willebrand factor (vWF) by ELISA, using antisera from DakoCytomation, essentially as described by Ingerslev 25 , and using pooled rat plasma for calibration.
Measurement of systolic blood pressure
To evaluate the effect of amlodipine on blood pressure, systolic blood pressure was measured in all groups during the first and second week after randomisation by tail-cuff plethysmography. The Blood Pressure System for Rats and Mice (RTBP1001, Harvard
Apparatus, Holliston, MA, USA) was used. Because the tails become more rigid as the mice age, the tail-cuff method did not allow blood pressure measurement at later time points.
Systolic blood pressure of each mouse was measured in triplicate.
Assessment of atherosclerosis development
31 weeks after the start of the study, mice were sacrificed under general fentanyl / fluanison / midazolam anaesthesia, the hearts were dissected, stored overnight in phosphate-buffered 3.8% formalin, embedded in paraffin, and sectioned. Sections of the aortic root (4 m thick) were stained with haematoxylin-phloxin-saffron (HPS). Serial crosssections were used for histological analysis. Per mouse, 4 sections at intervals of 50 m were used for quantification and typing of atherosclerotic lesions. Each section was subdivided into three segments representing the three aortic valves. Total lesion area was determined using image analysis software (Leica Qwin), the same operator performing all analyses. Per mouse, the average lesion area per section was calculated. For the determination of the severity of atherosclerosis, the lesions were classified into five categories as described before 16, 26 : type I) early fatty streak, type II) regular fatty streak, type III) mild plaque, type IV) moderate plaque, and type V) severe plaque. 
Results
Effects of amlodipine on cholesterol levels and blood pressure
To test whether amlodipine had any lipid-lowering properties a pilot study was performed.
At a concentration of 0.005% ( w / w ), amlodipine lowered plasma cholesterol levels and blood pressure in these mice. Because we aimed to have comparable cholesterol exposures in the amlodipine group and HC group, the amount of amlodipine in the diet was reduced to 0.003% ( w / w ). At this concentration, amlodipine no longer had a significant cholesterollowering, nor a blood pressure-lowering effect. This concentration was subsequently used in this study.
Mice that were treated with amlodipine had an average systolic blood pressure of 96 3 mmHg compared to 99 4 mmHg (n.s.) in mice that did not receive amlodipine.
Effects of amlodipine, atorvastatin, and a combination of both on plasma cholesterol levels and lipoprotein composition
No differences in body weight [ 
Atherosclerosis development
The atherosclerotic lesion area and the severity of the lesions were assessed in cross The severity of atherosclerosis was also expressed as the percentages of all segments that contained lesions [ Fig. 4A ]. This percentage was significantly reduced in all treatment groups ( 2 test). Furthermore, in the HC and atorvastatin groups all mice had lesions. In the amlodipine, the combination and the LC groups, mice were found that had no lesions at all (1 out of 13, 3 out of 16, and 1 out of 13 mice, respectively).
In addition, lesions were typed as being type I-III lesions (fatty streaks and mild plaques) or as type IV-V lesions (moderate and severe plaques). In the HC, amlodipine and LC groups, 10-20% of the lesions consisted of severe (type IV-V) lesions. In the atorvastatin and combination groups no severe lesions were found [ Fig. 4B ].
The effect of amlodipine and atorvastatin on levels of C-reactive protein, serum amyloid A and von Willebrand factor
At the endpoint of the study plasma CRP and SAA levels were measured as markers of general inflammation. Von Willebrand factor (vWF) in plasma was measured as a marker of endothelial activation. Plasma CRP levels were mildly elevated, on average 10 ± 6 mg/L, and did not differ between groups (table 2) .
SAA levels were significantly lower only in the atorvastatin + amlodipine-treated group, when compared to the HC group. vWF levels were lower in the atorvastatin + amlodipinetreated and LC groups as compared to the HC group (table 2) . There was no significant effect of either atorvastatin treatment alone or amlodipine treatment alone on SAA and vWF levels. 
Discussion
In this study, the anti-atherosclerotic effects of amlodipine, alone and in combination with atorvastatin, on early atherosclerosis development in the aortic root of male hypercholesterolemic E3L/CRP transgenic mice were quantified. Although amlodipine treatment did not significantly lower cholesterol levels or blood pressure, it reduced lesion area by 43%, indicating that amlodipine has an atheroprotective effect even in the absence of blood pressure lowering. The types of lesions found in the amlodipine-treated mice were mostly of type I-III, and 10-20% of type IV-V. In contrast to the HC and atorvastatin groups, in the amlodipine group as well as in the combination and LC groups some mice even had no lesions at all.
The HMG-CoA reductase inhibitor atorvastatin has potent anti-atherosclerotic effects in female E3L mice 18 . The present study shows identical results in male E3L/CRP transgenic mice. In male E3L/CRP mice, atorvastatin (4 mg/kg body weight per day) decreased plasma cholesterol levels by 42%, which was associated with a reduction in lesion area by 80% as compared to the HC group.
Delsing et al. 18 treated female E3L mice with atorvastatin (10 mg/kg body weight), amlodipine (2 mg/kg body weight) and a combination of both, and found no effect of amlodipine treatment on atherosclerosis. This contrasts with our findings in male E3L/CRP mice, which could be due to differences in the drug concentrations used, or due to the fact that the lesions Delsing et al. studied were advanced lesions, whereas we studied early lesions. Any benefit to be gained with amlodipine could be restricted to effects on the early stages of atherosclerosis only. This suggestion is supported by previous angiographic trials, that have shown that CAs can significantly reduce new lesion formation among patients with documented disease 4, 5 , while existing lesions were not affected.
Novel actions of amlodipine have been described which suggest that some of its atheroprotective effect may be due to its unique physical and pharmacokinetic properties.
Amlodipine is highly lipophilic which enables this drug to partition into the cell membrane. In vascular smooth muscle cells (VSMCs) derived from the atherosclerotic rabbit aorta amlodipine restores cholesterol-induced membrane bilayer abnormalities 27, 28 . Other proposed mechanisms through which CAs may affect atherosclerosis development include the inhibition of proliferation and migration of VSMCs 5, [29] [30] [31] , and the inhibition of lipoprotein oxidation 32, 33 . In addition, CAs modify the binding of monocytes to the endothelium and the synthesis of matrix components 34 .
The present study was designed to detect possible additive effects of atorvastatin and amlodipine treatment. Combined treatment with atorvastatin and amlodipine reduced lesion area more extensively than either treatment alone, leading to a reduction of lesion area by Our study included, as did the Encore 2 and the REGRESS study, a group treated with both a statin and a CA. In our mice, this combination therapy proved more effective than either compound alone, as in the two clinical studies cited. This may suggest that, in these respects, similar processes are involved in both human atherogenesis and in the murine model used.
In vitro and in vivo studies have documented cholesterol-lowering independent effects of statins that may be beneficial in atherosclerosis. These include the inhibition of leukocyte adhesion and migration 36 , and decreased production of cytokines. Stabilisation of the atherosclerotic plaque, reduction of oxidative stress 37 and inhibition of vascular inflammation have also been attributed to the use of statins 38 . It remains unclear, however, whether direct anti-inflammatory effects contribute to the beneficial role of statins, since cholesterol lowering per se is also anti-inflammatory 8 . In this study, we compared mice on a high-cholesterol diet supplemented with atorvastatin with mice on a low-cholesterol diet that resulted in a cholesterol exposure similar to that of the atorvastatin-treated mice. In this way we aimed to assess whether atorvastatin has any effects independent of lipid lowering. Lesion area was reduced by 30% in the atorvastatin group as compared to the LC group. However, this effect was not statistically significant, possibly because the extent of atherosclerosis was very low and the development of atherosclerosis was in the early phase in these groups. Therefore, we could not demonstrate an anti-atherosclerotic effect of atorvastatin in E3L/CRP mice that was independent of cholesterol lowering.
Besides lipid metabolism and high blood pressure, inflammation is an important component of atherosclerosis 39 , and plasma levels of inflammatory markers can be used as predictors of cardiovascular risk 40, 41 . Therefore, we measured serum amyloid A (SAA) at the 15 and was used here not to lower cholesterol too much, is apparently also ineffective during long-term treatment. Therefore, the absence of an effect of atorvastatin on CRP expression in the present study is most likely a dose-related effect.
Amlodipine alone had no effect on plasma vWF and SAA levels, indicating that the compound has no anti-inflammatory properties. Cholesterol lowering, either by atorvastatin or low-cholesterol feeding, lowered SAA levels in these mice; this effect did not reach significance. Using amlodipine in combination with atorvastatin resulted in a significant decrease of SAA levels when compared to the HC group. The effect of the different diets on vWF was similar, with the exception that lipid lowering did not reduce vWF levels equally in the atorvastatin and LC groups.
Conclusion
This study in ApoE*3-Leiden/hCRP transgenic mice has demonstrated the atheroprotective potential of amlodipine and atorvastatin on plaque development in the aortic root of male E3L/CRP transgenic mice. The atheroprotective effect of amlodipine was independent of blood pressure. Atorvastatin also had a strong anti-atherosclerotic effect. Co-treatment with amlodipine significantly enhanced this effect. Plasma CRP levels were not affected by any treatment.
